The conjugation of NLS-trastuzumab fab to the surface of BCMs was found to have no effect on the immunoreactivity of the antibody toward HER2+ breast cancer, and it allows uptake of radiobioconjugates into the cell nucleus. This evidence concerns the gene ERBB2 and breast cancer.